Filtered By:
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 303 results found since Jan 2013.
What Causes Irritability?
Discussion
Child abuse or non-accidental trauma is a clinical diagnosis. It is the constellation of history, physical examination, radiographic evaluation, laboratory testing and investigation that determines if child abuse has occurred. Irritability caused by fractures or other trauma can be a presenting symptom of abuse. Fractures can be a presentation but they are also common problems not associated with abuse. Femoral shaft fractures are estimated to account for only 1.6% of all fractures in children, therefore they are potentially more suspicious for child abuse. A review of femur fractures can be found here. A review...
Source: PediatricEducation.org - October 18, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system
AbstractThe ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly transmissible disease. SARS-CoV-2 is estimated to have infected over 153 million people and to have caused over 3.2 million global deaths since its emergence in December 2019. SARS-CoV-2 is the seventh coronavirus known to infect humans, and like other coronaviruses, SARS-CoV-2 infection is characterized by a variety of symptoms including general flu-like symptoms such as a fever, sore throat, fatigue, and shortness of breath. Severe cases often display signs of pneumonia, lymphopenia, acute kidney inj...
Source: Journal of NeuroVirology - September 28, 2021 Category: Neurology Source Type: research
New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)
Vaccine. 2021 Sep 7:S0264-410X(21)01097-5. doi: 10.1016/j.vaccine.2021.08.049. Online ahead of print.ABSTRACTBACKGROUND: Pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of pneumococcal disease, yet unmet medical need remains due to increased disease caused by non-vaccine serotypes (STs). V114 (VAXNEUVANCETM, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) is a 15-valent PCV containing 13 serotypes in licensed PCV13 and 2 additional serotypes (22F, 33F) which significantly contribute to pneumococcal disease burden. This phase 3 trial compared safety, toler...
Source: Vaccine - September 11, 2021 Category: Allergy & Immunology Authors: Heather L Platt Jose F Cardona Miwa Haranaka Howard I Schwartz Silvia Narejos Perez Anthony Dowell Chih-Jen Chang Ron Dagan Gretchen M Tamms Tina Sterling Leslie Morgan Yaru Shi Alison Pedley Luwy K Musey Ulrike K Buchwald Source Type: research
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)
CONCLUSION: Administration of V114 followed by PPSV23 was well tolerated and induced comparable antibody levels to PCV13 followed by PPSV23 in healthy adults aged ≥50 years.PMID:34489128 | DOI:10.1016/j.vaccine.2021.08.038
Source: Vaccine - September 7, 2021 Category: Allergy & Immunology Authors: Joon-Young Song Chih-Jen Chang Charles Andrews Javier Diez-Domingo Myoung-Don Oh Ron Dagan Jonathan Hartzel Alison Pedley Jianing Li Tina Sterling Gretchen Tamms Joseph A Chiarappa Jeannine Lutkiewicz Luwy Musey Yingmei Tu Ulrike K Buchwald V114-016 (PNEU Source Type: research
Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India
CONCLUSION: PCV13 vaccination was well tolerated with an acceptable safety profile in healthy subjects aged 6 to 17 years in India. This work further supports the safety profile of PCV13 for prevention of pneumococcal disease in this age group in India.PMID:34366142 | DOI:10.1016/j.vaccine.2021.07.055
Source: Vaccine - August 9, 2021 Category: Allergy & Immunology Authors: Jugesh Chhatwal Amita Sapru Balasubramanian Sundaram Bhaskar Shenoy Rohit Chand Kevin Yi Suresh Suroju Daniel A Scott Stephen Lockhart Source Type: research
Vaccine associated myocarditis revisited with COVID-19 mRNA vaccines
When I had reviewed the topic of vaccine associated myocarditis for an editorial in the BMH Medical Journal in 2017, most of the cases were associated with small pox vaccination [1]. There were also reports of streptococcal pneumonia vaccine and influenza vaccine associated myocarditis. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) used in the vaccine were also implicated in some cases [2,3].
While the large scale vaccination for small pox in an attempt to prepare for potential bioterrorism was the association in 2003 [4], COVID-19 mRNA vaccines are currently in the limelight for vaccine induced myocarditis...
Source: Cardiophile MD - July 22, 2021 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology Source Type: blogs
Analysis of two non-pharmacological pain management methods for vaccine injection pain in infants: A randomized controlled trial
CONCLUSION: Local cold and heat application methods applied to the vaccination area before a pneumoccal vaccine reduced vaccine-associated pain in the infants, and the application of cold was more effective than heat.PMID:34254654 | DOI:10.14744/agri.2020.54289
Source: Agri Dergisi - July 13, 2021 Category: Anesthesiology Authors: Tu ğba Güngör Özlem Öztürk Şahin Source Type: research
